|
1
|
Hidalgo M, Cascinu S, Kleeff J, Labianca
R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V:
Addressing the challenges of pancreatic cancer: Future directions
for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lefebvre AC, Maurel J, Boutreux S, Bouvier
V, Reimund JM, Launoy G and Arsene D: Pancreatic cancer: Incidence,
treatment and survival trends-1175 cases in Calvados (France) from
1978 to 2002. Gastroenterol Clin Biol. 33:1045–1051. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kocher HM and Alrawashdeh W: Pancreatic
cancer. BMJ Clin Evid. 2010(pii): 04092010.PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics in USA, 2018. CA Cancer J Clin. 68:7–30. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li HB, Zhou J and Zhao FQ: A prognostic
nomogram for disease-specific survival in patients with pancreatic
ductal adenocarcinoma of the head of the pancreas following
pancreaticoduodenectomy. Med Sci Monit. 24:6313–6321. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goldstein D, El-Maraghi RH, Hammel P,
Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S,
Tabernero J, Teixeira L, et al: Nab-Paclitaxel plus gemcitabine for
metastatic pancreatic cancer: Long-term survival from a phase III
trial. J Natl Cancer Inst. 107:1–10. 2015. View Article : Google Scholar
|
|
10
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cecconi D, Palmieri M and Donadelli M:
Proteomics in pancreatic cancer research. Proteomics. 11:816–828.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mostov KE, Kraehenbuhl JP and Blobel G:
Receptor-mediated transcellular transport of immunoglobulin:
Synthesis of secretory component as multiple and larger
transmembrane forms. Proc Natl Acad Sci USA. 77:7257–7261. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rojas R and Apodaca G: Immunoglobulin
transport across polarized epithelial cells. Nat Rev Mol Cell Biol.
3:944–955. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaetzel CS: The polymeric immunoglobulin
receptor: Bridging innate and adaptive immune responses at mucosal
surfaces. Immunol Rev. 206:83–99. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Phalipon A and Corthésy B: Novel functions
of the polymeric Ig receptor: Well beyond transport of
immunoglobulins. Trends Immunol. 24:55–58. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Denning GM: IL-4 and IFN-gamma
synergistically increase total polymeric IgA receptor levels in
human intestinal epithelial cells. Role of protein tyrosine
kinases. J Immunol. 156:4807–4814. 1996.PubMed/NCBI
|
|
17
|
Kvale D, Løvhaug D, Sollid LM and
Brandtzaeg P: Tumor necrosis factor-alpha up-regulates expression
of secretory component, the epithelial receptor for polymeric Ig. J
Immunol. 140:3086–3089. 1988.PubMed/NCBI
|
|
18
|
Poger ME, Hirsch BR and Lamm ME: Synthesis
of secretory component by colonic neoplasms. Am J Pathol.
82:327–338. 1976.PubMed/NCBI
|
|
19
|
Harris JP, Caleb MH and South MA:
Secretory component in human mammary carcinoma. Cancer Res.
35:1861–1864. 1975.PubMed/NCBI
|
|
20
|
Harris JP and South MA: Secretory
component: A glandular epithelial cell marker. Am J Pathol.
105:47–53. 1981.PubMed/NCBI
|
|
21
|
DeSouza LV, Krakovska O, Darfler MM,
Krizman DB, Romaschin AD, Colgan TJ and Siu KW: mTRAQ-based
quantification of potential endometrial carcinoma biomarkers from
archived formalin-fixed paraffin-embedded tissues. Proteomics.
10:3108–3116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rossel M, Billerey C, Bittard H, Ksiazek
P, Alber D, Revillard JP and Vuitton DA: Alterations in polymeric
immunoglobulin receptor expression and secretory component levels
in bladder carcinoma. Urol Res. 19:361–366. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rossel M, Seilles E, Voigt JJ, Vuitton D,
Legait N and Revillard JP: Polymeric Ig receptor expression in
hepatocellular carcinoma. Eur J Cancer. 28:1120–1124. 1992.
View Article : Google Scholar
|
|
24
|
Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R,
Chen Y, Gao X, Zhu Q, Yue X, et al: The role of polymeric
immunoglobulin receptor in inflammation-induced tumor metastasis of
human hepatocellular carcinoma. J Natl Cancer Inst. 103:1696–1712.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Berntsson J, Lundgren S, Nodin B, Uhlén M,
Gaber A and Jirström K: Expression and prognostic significance of
the polymeric immunoglobulin receptor in epithelial ovarian cancer.
J Ovarian Res. 7:262014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fristedt R, Gaber A, Hedner C, Nodin B,
Uhlén M, Eberhard J and Jirström K: Expression and prognostic
significance of the polymeric immunoglobulin receptor in esophageal
and gastric adenocarcinoma. J Transl Med. 12:832014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao T, Ying W, Li L, Hu Z, Ma Y, Jiao L,
Ma J, Cai Y, Lin D, Guo S, et al: An approach to studying lung
cancer-related proteins in human blood. Mol Cell Proteomics.
4:1480–1486. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rossel M, Brambilla E, Billaud M, Vuitton
DA, Blanc-Jouvan F, Biichle S and Revillard JP: Nonspecific
increased serum levels of secretory component in lung tumors:
Relationship to the gene expression of the transmembrane receptor
form. Am J Respir Cell Mol Biol. 9:341–346. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Makawita S, Smith C, Batruch I, Zheng Y,
Rückert F, Grützmann R, Pilarsky C, Gallinger S and Diamandis EP:
Integrated proteomic profiling of cell line conditioned media and
pancreatic juice for the identification of pancreatic cancer
biomarkers. Mol Cell Proteomics. 10:M111.008599. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kvale D, Norstein J, Meling GI, Børmer OP,
Brandtzaeg P, Langmark F and Rognum TO: Circulating secretory
component in relation to early diagnosis and treatment of liver
metastasis from colorectal carcinomas. J Clin Pathol. 45:568–571.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morton CL and Houghton PJ: Establishment
of human tumor xenografts in immunodeficient mice. Nat Protoc.
2:247–250. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chijiwa T, Kawai K, Noguchi A, Sato H,
Hayashi A, Cho H, Shiozawa M, Kishida T, Morinaga S, Yokose T, et
al: Establishment of patient-derived cancer xenografts in
immunodeficient NOG mice. Int J Oncol. 47:61–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Langmead B, Trapnell C, Pop M and Salzberg
SL: Ultrafast and memory-efficient alignment of short DNA sequences
to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Komura D, Isagawa T, Kishi K, Suzuki R,
Sato R, Tanaka M, Katoh H, Yamamoto S, Tatsuno K, Fukayama M, et
al: CASTIN: A system for comprehensive analysis of cancer-stromal
interactome. BMC Genomics. 17:8992016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pontén F, Jirström K and Uhlen M: The
human protein atlas-A tool for pathology. J Pathol. 216:387–393.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iida Y, Tanaka H, Sano H, Suzuki Y,
Shimizu H and Urano T: Ectopic expression of PCSK9 by smooth muscle
cells contributes to aortic dissection. Ann Vasc Surg. 48:195–203.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zijlstra M, Bernards N, de Hingh IH, van
de Wouw AJ, Goey SH, Jacobs EM, Lemmens VE and Creemers GJ: Does
long-term survival exist in pancreatic adenocarcinoma? Acta Oncol.
55:259–264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ying H, Dey P, Yao W, Kimmelman AC,
Draetta GF, Maitra A and DePinho RA: Genetics and biology of
pancreatic ductal adenocarcinoma. Genes Dev. 30:355–385. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jin K, Li G, Cui B, Zhang J, Lan H, Han N,
Xie B, Cao F, He K, Wang H, et al: Assessment of a novel VEGF
targeted agent using patient-derived tumor tissue xenograft models
of colon carcinoma with lymphatic and hepatic metastases. PLoS One.
6:e283842011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yada E, Wada S, Yoshida S and Sasada T:
Use of patient-derived xenograft mouse models in cancer research
and treatment. Futur Sci OA. 4:FSO2712018. View Article : Google Scholar
|
|
41
|
Hidalgo M, Amant F, Biankin AV, Budinská
E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo
GM, et al: Patient-derived xenograft models: An emerging platform
for translational cancer research. Cancer Discov. 4:998–1013. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cho SY, Kang W, Han JY, Min S, Kang J, Lee
A, Kwon JY, Lee C and Park H: An integrative approach to precision
cancer medicine using patient-derived xenografts. Mol Cells.
39:77–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fujii E, Suzuki M, Matsubara K, Watanabe
M, Chen YJ, Adachi K, Ohnishi Y, Tanigawa M, Tsuchiya M and Tamaoki
N: Establishment and characterization of in vivo human tumor models
in the NOD/SCID/γcnull mouse. Pathol Int. 58:559–567. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Erickson RA, Sayage-Rabie L and Beissner
RS: Factors predicting the number of EUS-guided fineneedle passes
for diagnosis of pancreatic malignancies. Gastrointest Endosc.
51:184–190. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
LeBlanc JK, Ciaccia D, Al-Assi MT, McGrath
K, Imperiale T, Tao LC, Vallery S, DeWitt J, Sherman S and Collins
E: Optimal number of EUS-guided fineneedle passes needed to obtain
acorrect diagnosis. Gastrointest Endosc. 59:475–481. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ohkuma R, Yada E, Ishikawa S, Komura D,
Ishizaki H, Tamada K, Kubota Y, Hamada K, Ishida H, Hirasawa Y, et
al: High expression of olfactomedin-4 is correlated with
chemoresistance and poor prognosis in pancreatic cancer. PLoS One.
15:e02267072020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
De Sousa Abreu R, Penalva LO, Marcotte EM
and Vogel C: Global signatures of protein and mRNA expression
levels. Mol Biosyst. 5:1512–1526. 2009.PubMed/NCBI
|
|
48
|
Schwanhüusser B, Busse D, Li N, Dittmar G,
Schuchhardt J, Wolf J, Chen W and Selbach M: Global quantification
of mammalian gene expression control. Nature. 473:337–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu L, Candille SI, Choi Y, Xie D, Jiang L,
Li-Pook-Than J, Tang H and Snyder M: Variation and genetic control
of protein abundance in humans. Nature. 499:79–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi
Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, et al:
Proteogenomic characterization of human colon and rectal cancer.
Nature. 513:382–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Arumugam P, Bhattacharya S, Chin-Aleong J,
Capaso M and Kocher HM: Expression of polymeric immunoglobulin
receptor and stromal activity in pancreatic ductal adenocarcinoma.
Pancreatology. 17:295–302. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fristedt R, Elebro J, Gaber A, Jonsson L,
Heby M, Yudina Y, Nodin B, Uhlén M, Eberhard J and Jirström K:
Reduced expression of the polymeric immunoglobulin receptor in
pancreatic and periampullary adenocarcinoma signifies tumour
progression and poor prognosis. PLoS One. 9:e1127282014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu F, Ye P, Bi T, Teng L, Xiang C, Wang
H, Li Y, Jin K and Mou X: COLORECTAL polymeric immunoglobulin
receptor expression is correlated with hepatic metastasis and poor
prognosis in colon carcinoma patients with hepatic metastasis.
Hepatogastroenterology. 61:652–659. 2014.PubMed/NCBI
|
|
54
|
Wang X, Du J, Gu P, Jin R and Lin X:
Polymeric immunoglobulin receptor expression is correlated with
poor prognosis in patients with osteosarcoma. Mol Med Rep.
9:2105–2110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Niu H, Wang K and Wang Y: Polymeric
immunoglobulin receptor expression is predictive of poor prognosis
in glioma patients. Int J Clin Exp Med. 7:21852014.PubMed/NCBI
|
|
56
|
Aguilar-Mahecha A, Hassan S, Ferrario C
and Basik M: Microarrays as validation strategies in clinical
samples: Tissue and protein microarrays. OMICS. 10:311–326. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Simon R and Sauter G: Tissue microarrays
for miniaturized high-throughput molecular profiling of tumors. Exp
Hematol. 30:1365–1372. 2002. View Article : Google Scholar : PubMed/NCBI
|
